No retraction, correction or concern found when last checked on Oct 27, 2026.
Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France
Florence Legrand-Abravanel, Nassim Kamar, Karine Sandres-Saune and 6 more
Emerging Infectious Diseases · 2011
Abstract
Infections with hepatitis E virus (HEV) in solid-organ transplant recipients can lead to chronic hepatitis.However, the incidence of de novo HEV infections after transplantation and risk for reactivation in patients with antibodies against HEV before transplantation are unknown.Pretransplant prevalence of these antibodies in 700 solid-organ transplant recipients at Toulouse University Hospital in France was 14.1%.We found no HEV reactivation among patients with antibodies against HEV at the fi rst annual checkup or by measuring liver enzyme activities and HEV RNA.In contrast, we found 34 locally acquired HEV infections among patients with no antibodies against HEV, 47% of whom had a chronic infection, resulting in an incidence of 3.2/100 person-years.Independent risk factors for HEV infection were an age <52 years at transplantation and receiving a liver transplant.Effective prophylactic measures that include those for potential zoonotic infections should reduce the risk for HEV transmission in this population. L arge epidemics of hepatitis E have occurred in Asia,Africa, and Latin America where sanitation is suboptimal (1).The numbers of non-travel-associated hepatitis E Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.
MEDSCAPE CME
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscapecme.com/journal/eid; (4) view/print certificate.
Release date: December 22, 2010; Expiration date: December 22, 2011
Learning Objectives
Upon completion of this activity, participants will be able to:
Describe factors associated with higher risk for HEV seroconversion and development of chronic disease among liver and kidney transplant patients.
MEDSCAPE CME Editor
Thomas J. Gryczan, MS, Technical Writer-Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.
MEDSCAPE CME AUTHOR
Desiree Lie, MD, MSEd, Clinical Professor; Director of Research and Faculty Development, Department of Family Medicine, University of California, Irvine at Orange. Disclosure: Désirée Lie, MD, MSEd, has disclosed the following relevant financial relationship: served as a nonproduct speaker for "Topics in Health" for Merck Speaker Services.
AUTHORS
Disclosures: Florence Legrand-Abravanel, PharmD, PhD; Nassim Kamar, MD, PhD; Karine Sandres-Saune, PharmD, PhD; Sebastien Lhomme, PharmD; Jean-Michel Mansuy, MD; Fabrice Muscari, MD, PhD; Federico Sallusto, MD; Lionel Rostaing, MD, PhD; and Jacques Izopet, PharmD, PhD, have disclosed no relevant financial relationships.
References 39
- 1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 7.
- 8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 26.
- 27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 39.
Cited by papers we hold 4
- Epidemiological Characteristics and Clinical Manifestations of Hepatitis E in a Tertiary Hospital in China: A Retrospective Study · 2022Not checked
- Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes · 2018Not checked
- Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France · 2012No notice
- Hepatitis E Virus Antibodies in Blood Donors, France · 2011No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.